Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common variant of non-Hodgkins lymphoma and accounts for 3060% of all non-Hodgkins lymphomas, with increasing incidence increases with age. Currently, the prognosis is assessed using the International Prognostic Index. In recent years, in all European regions, there has been a significant improvement in survival in DLBCL due to the addition of rituximab to standard chemotherapy (CHOP protocol). However, despite significant advances in treatment, long-term remission is only achieved in half of the patients. Laryngeal lesions with this variant of lymphomas is described only in a few articles. There is evidence of various chemotherapeutic regimens effective in this type of lymphoma; in some publications, the authors suggest the use of radiation therapy.
The article presents a clinical case of successful treatment of a patient (chemotherapy + radiation therapy) with diffuse large B-cell lymphoma with laryngeal involvement. with resulting remission. In addition, a review of the literature describing the most common types of lymphomas is presented. The authors set a goal to raise the awareness of physicians about a rare histological variant of laryngeal tumors with a rapid increase in clinical manifestations and the development of life-threatening conditions.
Reference16 articles.
1. World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Volume 2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, et al, editors. Lyon: International agency for research on cancer; 2017.
2. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence
3. Zykova TA, Engibarjan MA, Pustovaja IV., i dr. Vyjavleny razlichija serologicheskogo profilja inficirovanija virusom Jepshtejna-Barr u bol’nyh s opuholjami oblasti golovy/shei i limfomami. In: Materialy V Peterburgskogo mezhdunarodnogo onkologicheskogo foruma «Belye nochi»; 2019 Jun 20–23; Saint-Petersburg. Saint-Petersburg: Avtonomnaja nekommercheskaja nauchno-medicinskaja organizacija «Voprosy onkologii»; 2019. P. 116.
4. The use of immunotherapy for the treatment of refractory forms of Hodgkin lymphoma in real clinical practice.
5. Primary mediastinal large B-cell lymphoma with a rare <i>ALK</i> gene mutation